Zoetis (NYSE:ZTS) – Stock analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for shares of Zoetis in a report released on Friday, April 13th. Jefferies Group analyst I. Hilliker expects that the company will post earnings per share of $0.71 for the quarter. Jefferies Group currently has a “Buy” rating and a $96.00 target price on the stock. Jefferies Group also issued estimates for Zoetis’ FY2018 earnings at $3.07 EPS, FY2019 earnings at $3.56 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $4.56 EPS and FY2022 earnings at $5.09 EPS.
Several other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price on the stock. in a report on Saturday, January 13th. Bank of America lifted their price objective on shares of Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 16th. Morgan Stanley downgraded shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price objective on the stock. in a report on Monday, March 19th. They noted that the move was a valuation call. Craig Hallum reiterated a “buy” rating and issued a $85.00 price objective (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average price target of $80.89.
Shares of ZTS stock opened at $83.57 on Monday. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85. The company has a market cap of $40,741.90, a price-to-earnings ratio of 34.82, a P/E/G ratio of 1.88 and a beta of 0.96. Zoetis has a 52 week low of $53.00 and a 52 week high of $85.73.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company posted $0.47 EPS.
Institutional investors and hedge funds have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. bought a new position in Zoetis during the fourth quarter worth $108,000. Steward Partners Investment Advisory LLC bought a new position in Zoetis during the third quarter worth $114,000. We Are One Seven LLC bought a new position in Zoetis during the fourth quarter worth $120,000. Premia Global Advisors LLC bought a new position in Zoetis during the fourth quarter worth $122,000. Finally, Icon Wealth Partners LLC bought a new position in Zoetis during the fourth quarter worth $127,000. Institutional investors and hedge funds own 92.44% of the company’s stock.
In related news, insider Roman Trawicki sold 23,885 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total transaction of $1,958,570.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,952 shares of company stock worth $9,219,843. 0.35% of the stock is owned by corporate insiders.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.60%. Zoetis’s payout ratio is 20.83%.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.